Oral alkaline phosphatase - Theriva Biologics
Alternative Names: Oral intestinal alkaline phosphatase - Theriva Biologics; SYN-020Latest Information Update: 28 Apr 2025
At a glance
- Originator Synthetic Biologics
- Developer Theriva Biologics
- Class Anti-inflammatories; Anti-ischaemics; Hepatoprotectants; Phosphoric monoester hydrolases; Recombinant proteins
- Mechanism of Action Alkaline phosphatase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Coeliac disease; Inflammatory bowel diseases; Metabolic syndrome; Non-alcoholic fatty liver disease; Radiation injuries
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Coeliac disease(In volunteers) in USA (PO, Controlled release)
- 28 Apr 2025 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases(In volunteers) in USA (PO, Controlled release)
- 28 Apr 2025 No recent reports of development identified for phase-I development in Metabolic-syndrome(In volunteers) in USA (PO, Controlled release)